Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celltrion
Celltrion has become the latest firm to file for a tocilizumab biosimilar in the US, submitting its CT-P47 candidate to the FDA.
Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.